.svg)
Retatrutide FDA Approval Status: June 2026 Update
Updated monthly. Current trial status, NDA timeline, and realistic approval date — no speculation.
What's New: June 2026 Update
- TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients — Eli Lilly's pivotal Phase 3 obesity trial met all primary and key secondary endpoints
- 45.3% of patients on 12mg lost ≥30% of body weight — surgical-level outcomes confirmed in the largest retatrutide trial to date
- 104-week extension: patients with BMI ≥35 reached up to 30.3% average weight loss — weight loss did not plateau at 80 weeks
- NDA submission now imminent: Eli Lilly confirmed regulatory submission anticipated in 2026, following TRIUMPH-1 and TRIUMPH-4 data
- TRIUMPH-2 and TRIUMPH-3 results still expected later in 2026 — this page updates monthly
Current Status: Where Things Stand
Retatrutide is an investigational medication developed by Eli Lilly. It is not FDA approved and not available by prescription as of June 2026.
Two Phase 3 trials have now completed. TRIUMPH-4 demonstrated 28.7% average weight loss at 68 weeks (December 2025), and TRIUMPH-1 confirmed 28.3% at 80 weeks (May 21, 2026) — results that match bariatric surgery outcomes.
TRIUMPH-1 has reported. On May 21, 2026, Eli Lilly announced that the pivotal general obesity trial — 2,339 participants, 80 weeks — confirmed and extended TRIUMPH-4's results. The 12mg dose produced 28.3% average weight loss, with 45.3% of participants achieving ≥30% loss. Eli Lilly now has the primary efficacy dataset required for an NDA filing, which is anticipated before the end of 2026.
TRIUMPH Trial Program: Full Status
Key context: TRIUMPH-1 and TRIUMPH-4 data together will form the primary efficacy package for the NDA filing. TRIUMPH-2 will support a potential diabetes indication. TRIUMPH-CVOT is not required for initial obesity approval but will be critical for long-term payer coverage.
FDA Approval Timeline: Step by Step
Timeline assumes priority review designation and no unexpected safety signals. Standard review would delay approval by approximately 2–3 months.
What to Watch in the Second Half of 2026
The next six months are the most consequential period in retatrutide's development:
TRIUMPH-1 — CONFIRMED (May 21, 2026)
Eli Lilly announced positive topline results from TRIUMPH-1 on May 21, 2026. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity (without diabetes), the 12mg dose produced 28.3% average weight loss at 80 weeks. 45.3% of participants lost ≥30% of body weight — outcomes previously associated only with bariatric surgery. In a prespecified 104-week extension subgroup (BMI ≥35), average weight loss reached 30.3%, confirming that weight loss does not plateau at 80 weeks. The safety profile was consistent with TRIUMPH-4, with a discontinuation rate of 11.3%.
TRIUMPH-2 announcement (Q3–Q4 2026)
Results in diabetic patients will determine whether retatrutide can pursue a dual obesity + diabetes indication. This is commercially significant: diabetes coverage by Medicare and most commercial insurers is broader than obesity coverage.
NDA filing (Q4 2026)
If both TRIUMPH-1 and TRIUMPH-2 are positive, Eli Lilly is expected to submit the New Drug Application before year-end. This submission triggers the formal FDA review clock.
What This Means for Patients
If you are waiting for retatrutide:
Retatrutide will not be available by prescription before late 2027 at the absolute earliest, and realistically Q1–Q2 2028. Waiting for it means delaying obesity treatment by 18–24 months.
If you qualify for existing medications — tirzepatide (Zepbound, 20.9% average weight loss) or semaglutide (Wegovy, 14.9% average weight loss) — the clinical case for waiting is weak. Starting treatment now with an approved medication, then reassessing in 2028, is the approach most obesity specialists recommend.
If you want to access retatrutide before approval:
The only legal pathway is clinical trial enrollment. Check ClinicalTrials.gov for ongoing TRIUMPH trials or extension studies. Most require BMI ≥30, no prior bariatric surgery, and stable weight for 3+ months. You may be randomized to placebo — a 50% chance in most trials.
If you are already on tirzepatide or semaglutide:
There is no mechanism to switch to retatrutide at this time. Retatrutide is not available. Continue current treatment and monitor TRIUMPH-1 results — they will clarify whether switching in 2028 makes sense for your situation.
Sources & References
- Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
- Eli Lilly Q1 2026 Earnings Call — NDA filing timeline confirmation
- Jastreboff AM, et al. TRIUMPH-4 Phase 3 Results. N Engl J Med. December 2025
- Jastreboff AM, et al. Retatrutide Phase 2. N Engl J Med. 2023;389:514–526
- ClinicalTrials.gov: TRIUMPH program registry entries
- FDA guidance: Developing Products for Weight Management (2022)
Medical Disclaimer: This article is for informational purposes only. Retatrutide is investigational and not FDA approved. Consult your healthcare provider before making any treatment decisions.
Frequently Asked Questions
TRIUMPH-1, the pivotal general obesity trial (2,339 patients, 80 weeks), reported positive results on May 21, 2026 — 28.3% average weight loss at 12mg.
Based on current timelines: NDA submission Q4 2026, FDA review 10–12 months, projected approval late 2027 under priority review or Q1 2028 under standard review. Market launch would follow 1–3 months after approval, placing patient access at Q1–Q2 2028. This timeline reflects TRIUMPH-1 positive results (May 21, 2026) and assumes no unexpected safety signals emerge from ongoing trials.
TRIUMPH-1 (general obesity, 2,339 patients, 80 weeks) reported positive results on May 21, 2026 — 28.3% weight loss at 12mg, confirming primary and key secondary endpoints.
No. Retatrutide is not available by prescription. The only way to access it is through clinical trial enrollment — check ClinicalTrials.gov for ongoing TRIUMPH trials. Most require BMI ≥30 (or ≥27 with comorbidity) and no prior bariatric surgery. Prescription access is not expected until Q1–Q2 2028 at the earliest following FDA approval.
Related Topics
Evidence-based articles to support your journey toward sustainable health.
Register your interest in Retatrutide
Retatrutide is currently not available, but once it is approved, you’ll be the first to get notified. Sign up now and stay informed.
Simple one-time sign-up
Early access to availability updates
Exclusive status among the first users
Advantage over non-registered users
Disclaimer: This is not medical advice. Retatrutide is investigational and not FDA-approved. Consult your doctor. Full Medical Disclaimer.